Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Liver Cirrhosis

  Free Subscription


Articles published in Hepatology

Retrieve available abstracts of 208 articles:
HTML format
Text format



Single Articles


    October 2017
  1. YANG JD, Mannalithara A, Piscitello AJ, Kisiel JB, et al
    Impact of Surveillance for Hepatocellular Carcinoma on Survival in Patients with Compensated Cirrhosis.
    Hepatology. 2017 Oct 12. doi: 10.1002/hep.29594.
    PubMed     Text format     Abstract available


  2. MONTANO-LOZA AJ, Mazurak VC, Ebadi M, Meza-Junco J, et al
    Visceral adiposity increases risk for hepatocellular carcinoma in male patients with cirrhosis and recurrence after liver transplant.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29578.
    PubMed     Text format     Abstract available


  3. MACDONALD S, Andreola F, Bachtiger P, Amoros A, et al
    Cell death markers in cirrhotic patients with acute decompensation.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29581.
    PubMed     Text format     Abstract available


  4. ALBILLOS A, Zamora J, Martinez J, Arroyo D, et al
    Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient meta-analysis.
    Hepatology. 2017;66:1219-1231.
    PubMed     Text format     Abstract available


  5. SO-ARMAH KA, Lim JK, Lo Re V, Tate JP, et al
    FIB-4 stage of liver fibrosis predicts incident heart failure among HIV-infected and uninfected patients.
    Hepatology. 2017;66:1286-1295.
    PubMed     Text format     Abstract available


  6. BANGEN JM, Hammerich L, Sonntag R, Baues M, et al
    Targeting CCl4 -induced liver fibrosis by RNA interference-mediated inhibition of cyclin E1 in mice.
    Hepatology. 2017;66:1242-1257.
    PubMed     Text format     Abstract available


    September 2017
  7. WYLES D, Poordad F, Wang S, Alric L, et al
    Glecaprevir/Pibrentasvir for HCV Genotype 3 Patients with Cirrhosis and/or Prior Treatment Experience: A Partially Randomized Phase III Clinical Trial.
    Hepatology. 2017 Sep 19. doi: 10.1002/hep.29541.
    PubMed     Text format     Abstract available


  8. CESARI M, Frigo AC, Tonon M, Angeli P, et al
    Cardiovascular predictors of death in patients with cirrhosis.
    Hepatology. 2017 Sep 13. doi: 10.1002/hep.29520.
    PubMed     Text format     Abstract available


  9. BORENTAIN P, Colson P, Bolon E, Gauchez P, et al
    Hepatocellular carcinoma complicating hepatitis E virus-related cirrhosis.
    Hepatology. 2017 Sep 5. doi: 10.1002/hep.29508.
    PubMed     Text format    


    August 2017
  10. DE HAAS RJ, Lim C, Bhangui P, Salloum C, et al
    Curative Salvage Liver Transplantation in Cirrhotic patients with Hepatocellular Carcinoma: An intention-to-treat analysis.
    Hepatology. 2017 Aug 14. doi: 10.1002/hep.29468.
    PubMed     Text format     Abstract available


  11. LAI JC, Covinsky KE, Dodge JL, Boscardin WJ, et al
    Development of a novel frailty index to predict mortality in patients with end-stage liver disease.
    Hepatology. 2017;66:564-574.
    PubMed     Text format     Abstract available


    July 2017
  12. SAUERBRUCH T
    Continuation of non-selective beta-blockers for patients with liver cirrhosis and hemodynamic non-response?
    Hepatology. 2017 Jul 22. doi: 10.1002/hep.29394.
    PubMed     Text format    


  13. PEDERSEN JS, Kimer N, Henriksen JH, Bendtsen F, et al
    The Royal Free Hospital Cirrhosis Glomerular Filtration Rate: Validation in a Danish Cohort.
    Hepatology. 2017 Jul 20. doi: 10.1002/hep.29386.
    PubMed     Text format    


  14. KALAFATELI M, Tsochatzis EA
    Reply to "The Royal Free Hospital Cirrhosis Glomerular Filtration Rate: Validation in a Danish Cohort."
    Hepatology. 2017 Jul 20. doi: 10.1002/hep.29391.
    PubMed     Text format    


  15. ARDEVOL A, Ibanez-Sanz G, Profitos J, Aracil C, et al
    Survival of patients with cirrhosis and acute peptic ulcer bleeding compared with variceal bleeding using current first-line therapies.
    Hepatology. 2017 Jul 17. doi: 10.1002/hep.29370.
    PubMed     Text format     Abstract available


  16. UNALP-ARIDA A, Ruhl CE
    Liver fibrosis scores predict liver disease mortality in the United States population.
    Hepatology. 2017;66:84-95.
    PubMed     Text format     Abstract available


    May 2017
  17. MARKWARDT D, Holdt L, Steib C, Benesic A, et al
    Plasma Cystatin C is a predictor of renal dysfunction, ACLF and mortality in patients with acutely decompensated liver cirrhosis.
    Hepatology. 2017 May 25. doi: 10.1002/hep.29290.
    PubMed     Text format     Abstract available


  18. TSOCHATZIS EA, Bosch J
    Statins in cirrhosis - ready for prime time.
    Hepatology. 2017 May 22. doi: 10.1002/hep.29277.
    PubMed     Text format    


    April 2017
  19. SONG Y, Liu C, Liu X, Trottier J, et al
    H19 promotes cholestatic liver fibrosis by preventing ZEB1-mediated inhibition of EpCAM.
    Hepatology. 2017 Apr 13. doi: 10.1002/hep.29209.
    PubMed     Text format     Abstract available


  20. HADJIHAMBI A, De Chiara F, Hosford PS, Habtetion A, et al
    Ammonia mediates cortical hemichannel dysfunction in rodent models of chronic liver disease.
    Hepatology. 2017;65:1306-1318.
    PubMed     Text format     Abstract available


  21. BALIGAR P, Kochat V, Arindkar SK, Equbal Z, et al
    Bone marrow stem cell therapy partially ameliorates pathological consequences in livers of mice expressing mutant human alpha1-antitrypsin.
    Hepatology. 2017;65:1319-1335.
    PubMed     Text format     Abstract available


  22. HALL Z, Bond NJ, Ashmore T, Sanders F, et al
    Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease.
    Hepatology. 2017;65:1165-1180.
    PubMed     Text format     Abstract available


  23. PETTA S, Wong VW, Camma C, Hiriart JB, et al
    Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values.
    Hepatology. 2017;65:1145-1155.
    PubMed     Text format     Abstract available


    March 2017
  24. CHANG FM, Wang YP, Lang HC, Tsai CF, et al
    Statins decrease the risk of decompensation in HBV- and HCV-related cirrhosis: A population-based study.
    Hepatology. 2017 Mar 20. doi: 10.1002/hep.29172.
    PubMed     Text format     Abstract available


  25. DE MATTOS AZ, Miozzo SA, Tovo CV, de Mattos AA, et al
    Risks of proton pump inhibitors for cirrhotic patients - the controversy remains.
    Hepatology. 2017 Mar 20. doi: 10.1002/hep.29132.
    PubMed     Text format    


  26. MOLLER S, Hove JD
    Assessment of systolic function in the evaluation of patients with cirrhosis.
    Hepatology. 2017 Mar 20. doi: 10.1002/hep.29163.
    PubMed     Text format    


  27. CAMPAGNA F, Montagnese S, Ridola L, Senzolo M, et al
    The animal naming test: An easy tool for the assessment of hepatic encephalopathy.
    Hepatology. 2017 Mar 8. doi: 10.1002/hep.29146.
    PubMed     Text format     Abstract available


  28. LI X, Liu R, Yang J, Sun L, et al
    The role of LncRNA H19 in gender disparity of cholestatic liver injury in Mdr2-/- mice.
    Hepatology. 2017 Mar 8. doi: 10.1002/hep.29145.
    PubMed     Text format     Abstract available


  29. WAN Y, Meng F, Wu N, Zhou T, et al
    Substance P increases liver fibrosis by differential changes in senescence of cholangiocytes and hepatic stellate cells.
    Hepatology. 2017 Mar 3. doi: 10.1002/hep.29138.
    PubMed     Text format     Abstract available


  30. MAIERS JL, Kostallari E, Mushref M, deAssuncao TM, et al
    The unfolded protein response mediates fibrogenesis and collagen I secretion through regulating TANGO1 in mice.
    Hepatology. 2017;65:983-998.
    PubMed     Text format     Abstract available


  31. ZHU B, Wei L, Rotile N, Day H, et al
    Combined magnetic resonance elastography and collagen molecular magnetic resonance imaging accurately stage liver fibrosis in a rat model.
    Hepatology. 2017;65:1015-1025.
    PubMed     Text format     Abstract available


  32. KISSELEVA T
    The origin of fibrogenic myofibroblasts in fibrotic liver.
    Hepatology. 2017;65:1039-1043.
    PubMed     Text format     Abstract available


    February 2017
  33. DAM G, Vilstrup H, Watson H, Jepsen P, et al
    Reply to letter from de Mattos and colleagues: Risks of proton pump inhibitors for cirrhotic patients - the controversy remains.
    Hepatology. 2017 Feb 21. doi: 10.1002/hep.29131.
    PubMed     Text format    


  34. YOTTI R, Ripoll C, Benito Y, Catalina MV, et al
    Left ventricular systolic function is associated to sympathetic nervous activity and markers of inflammation in cirrhosis.
    Hepatology. 2017 Feb 13. doi: 10.1002/hep.29104.
    PubMed     Text format     Abstract available


  35. KUMAR A, Davuluri G, deSilva RN, Engelen MP, et al
    Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis.
    Hepatology. 2017 Feb 13. doi: 10.1002/hep.29107.
    PubMed     Text format    


  36. BRUDEN DJ, McMahon BJ, Townshend-Bulson L, Gounder P, et al
    Risk of End Stage Liver Disease, Hepatocellular Carcinoma and Liver-Related Death By Fibrosis Stage in the Hepatitis C Alaska Cohort.
    Hepatology. 2017 Feb 13. doi: 10.1002/hep.29115.
    PubMed     Text format     Abstract available


  37. FERNANDEZ CARRILLO C, Lens S, Llop E, Pascasio JM, et al
    Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of MELD: Analysis of data from the Hepa-C registry.
    Hepatology. 2017 Feb 7. doi: 10.1002/hep.29097.
    PubMed     Text format     Abstract available


  38. ZUBIETE-FRANCO I, Fernandez-Tussy P, Barbier-Torres L, Simon J, et al
    Deregulated neddylation in liver fibrosis.
    Hepatology. 2017;65:694-709.
    PubMed     Text format     Abstract available


  39. TEDESCO D, Thapa M, Gumber S, Elrod EJ, et al
    CD4+ Foxp3+ T cells promote aberrant immunoglobulin G production and maintain CD8+ T-cell suppression during chronic liver disease.
    Hepatology. 2017;65:661-677.
    PubMed     Text format     Abstract available


    January 2017
  40. VILASECA M, Garcia-Caldero H, Lafoz E, Garcia-Irigoyen O, et al
    The anticoagulant Rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells.
    Hepatology. 2017 Jan 31. doi: 10.1002/hep.29084.
    PubMed     Text format     Abstract available


  41. WANG Y, Vincent R, Yang J, Asgharpour A, et al
    Dual photon microscopy based quantitation of fibrosis-related parameters (q-FP) to model disease progression in steatohepatitis.
    Hepatology. 2017 Jan 30. doi: 10.1002/hep.29090.
    PubMed     Text format     Abstract available


  42. WANG Y, Aoki H, Yang J, Peng K, et al
    The role of S1PR2 in bile acid-induced cholangiocyte proliferation and cholestasis-induced liver injury in mice.
    Hepatology. 2017 Jan 24. doi: 10.1002/hep.29076.
    PubMed     Text format     Abstract available


  43. HARGROVE L, Kennedy L, Demieville J, Jones H, et al
    BDL-induced biliary hyperplasia, hepatic injury and fibrosis are reduced in mast cell deficient Kitw-sh mice.
    Hepatology. 2017 Jan 24. doi: 10.1002/hep.29079.
    PubMed     Text format     Abstract available


  44. THABET K, Chan HL, Petta S, Mangia A, et al
    The MBOAT7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B.
    Hepatology. 2017 Jan 20. doi: 10.1002/hep.29064.
    PubMed     Text format     Abstract available


  45. SABATE A, Blasi A
    Thromboelastography and blood product usage in cirrhosis with severe coagulopathy.
    Hepatology. 2017 Jan 19. doi: 10.1002/hep.29061.
    PubMed     Text format    


  46. VILLANUEVA C, Graupera I, Aracil C, Alvarado E, et al
    A Randomized trial to assess whether portal pressure guided therapy to prevent variceal rebleeding improves survival in cirrhosis.
    Hepatology. 2017 Jan 18. doi: 10.1002/hep.29056.
    PubMed     Text format     Abstract available


  47. DRIVER R, Rowe IA
    What is the benefit of early follow-up after hospitalization for patients with cirrhosis?
    Hepatology. 2017 Jan 18. doi: 10.1002/hep.29060.
    PubMed     Text format    


  48. MARONI L, Hohenester SD, van de Graaf SF, Tolenaars D, et al
    Knockout of the Primary Sclerosing Cholangitis-Risk Gene Fut2 Causes Liver Disease in Mice.
    Hepatology. 2017 Jan 5. doi: 10.1002/hep.29029.
    PubMed     Text format     Abstract available


  49. ALCARAZ-QUILES J, Titos E, Casulleras M, Pavesi M, et al
    Polymorphisms in the IL-1 gene cluster influence systemic inflammation in patients at risk for acute-on-chronic liver failure.
    Hepatology. 2017;65:202-216.
    PubMed     Text format     Abstract available


  50. DECARIS ML, Li KW, Emson CL, Gatmaitan M, et al
    Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood.
    Hepatology. 2017;65:78-88.
    PubMed     Text format     Abstract available


    December 2016
  51. TANDON P, Raman M, Mourtzakis M, Merli M, et al
    A Practical Approach to Nutritional Screening and Assessment in Cirrhosis.
    Hepatology. 2016 Dec 27. doi: 10.1002/hep.29003.
    PubMed     Text format     Abstract available


  52. BERZIGOTTI A, Albillos A, Villanueva C, Genesca J, et al
    Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The sportdiet study.
    Hepatology. 2016 Dec 20. doi: 10.1002/hep.28992.
    PubMed     Text format     Abstract available


  53. KAFFE E, Katsifa A, Xylourgidis N, Ninou I, et al
    Hepatocyte Autotaxin expression promotes liver fibrosis and cancer.
    Hepatology. 2016 Dec 16. doi: 10.1002/hep.28973.
    PubMed     Text format     Abstract available


    November 2016
  54. ASKGAARD G, Leon DA, Kjaer MS, Deleuran T, et al
    Risk for alcoholic liver cirrhosis after an initial hospital contact with alcohol problems: A nationwide prospective cohort study.
    Hepatology. 2016 Nov 16. doi: 10.1002/hep.28943.
    PubMed     Text format     Abstract available


  55. NEWBERRY EP, Xie Y, Kennedy SM, Graham MJ, et al
    Prevention of hepatic fibrosis with liver microsomal triglyceride transfer protein deletion in Liver fatty acid binding protein null mice.
    Hepatology. 2016 Nov 14. doi: 10.1002/hep.28941.
    PubMed     Text format     Abstract available


  56. CALDWELL S, Lisman T
    The cirrhotic platelet: Shedding light on an enigma.
    Hepatology. 2016 Nov 7. doi: 10.1002/hep.28931.
    PubMed     Text format    


  57. MASSEY VL, Dolin CE, Poole LG, Hudson SV, et al
    The hepatic "matrisome" responds dynamically to injury: Characterization of transitional changes to the extracellular matrix in mice.
    Hepatology. 2016 Nov 5. doi: 10.1002/hep.28918.
    PubMed     Text format     Abstract available


  58. DESBOROUGH MJ, Kahan BC, Stanworth SJ, Jairath V, et al
    Fibrinogen as an independent predictor of mortality in decompensated cirrhosis and bleeding.
    Hepatology. 2016 Nov 3. doi: 10.1002/hep.28915.
    PubMed     Text format    


  59. DROLZ A, Fuhrmann V
    "Fibrinogen as an independent predictor of mortality in decompensated cirrhosis and bleeding".
    Hepatology. 2016 Nov 3. doi: 10.1002/hep.28914.
    PubMed     Text format    


    October 2016
  60. GARCIA-TSAO G, Abraldes J, Berzigotti A, Bosch J, et al
    Portal Hypertensive Bleeding in Cirrhosis: Risk Stratification, Diagnosis and Management - 2016 Practice Guidance by the American Association for the Study of Liver Diseases.
    Hepatology. 2016 Oct 27. doi: 10.1002/hep.28906.
    PubMed     Text format    


  61. KALAFATELI M, Wickham F, Burniston M, Cholongitas E, et al
    Development and validation of a mathematical equation to estimate glomerular filtration rate in cirrhosis: The rfh cirrhosis Gfr.
    Hepatology. 2016 Oct 25. doi: 10.1002/hep.28891.
    PubMed     Text format     Abstract available


  62. TANDON P, Reddy KR, O'Leary JG, Garcia-Tsao G, et al
    A Karnofsky performance status-based score predicts death after hospital discharge in patients with cirrhosis.
    Hepatology. 2016 Oct 24. doi: 10.1002/hep.28900.
    PubMed     Text format     Abstract available


  63. ATIQ O, Tiro J, Yopp AC, Muffler A, et al
    An Assessment of Benefits and Harms of Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis.
    Hepatology. 2016 Oct 24. doi: 10.1002/hep.28895.
    PubMed     Text format     Abstract available


  64. KIMER N, Pedersen JS, Busk TM, Gluud LL, et al
    Rifaximin has no effect on hemodynamics in decompensated cirrhosis - A randomized, double blind, placebo controlled trial.
    Hepatology. 2016 Oct 24. doi: 10.1002/hep.28898.
    PubMed     Text format     Abstract available


  65. LABONTE AC, Sung SJ, Jennelle LT, Dandekar AP, et al
    Expression of scavenger receptor-AI promotes alternative activation of murine macrophages to limit hepatic inflammation and fibrosis.
    Hepatology. 2016 Oct 22. doi: 10.1002/hep.28873.
    PubMed     Text format     Abstract available


  66. PARIKH ND, Marshall VD, Singal AG, Nathan H, et al
    Survival and Cost-Effectiveness of Sorafenib Therapy in Advanced Hepatocellular Carcinoma: An Analysis of the SEER-Medicare Database.
    Hepatology. 2016 Oct 22. doi: 10.1002/hep.28881.
    PubMed     Text format     Abstract available


  67. WRANKE A, Calle Serrano B, Heidrich B, Kirschner J, et al
    Antiviral treatment and liver-related complications in hepatitis delta.
    Hepatology. 2016 Oct 22. doi: 10.1002/hep.28876.
    PubMed     Text format     Abstract available


  68. MAROT A, Vandenbulcke H, Knebel JF, Doerig C, et al
    External validation of the nomogram for individualized prediction of HCC occurrence in patients with HCV-related compensated cirrhosis.
    Hepatology. 2016 Oct 13. doi: 10.1002/hep.28865.
    PubMed     Text format    


    September 2016
  69. ALI KHAN M, Cholankeril G, Howden CW
    Are proton pump inhibitors a threat for spontaneous bacterial peritonitis and hepatic encephalopathy in cirrhosis? Not so fast.
    Hepatology. 2016 Sep 30. doi: 10.1002/hep.28858.
    PubMed     Text format    


  70. LO GH
    The risk of bleeding after invasive procedures in cirrhotics with severe coagulopathy.
    Hepatology. 2016 Sep 26. doi: 10.1002/hep.28855.
    PubMed     Text format    


  71. RAPARELLI V, Basili S, Carnevale R, Napoleone L, et al
    Low-grade endotoxemia and platelet activation in cirrhosis.
    Hepatology. 2016 Sep 19. doi: 10.1002/hep.28853.
    PubMed     Text format     Abstract available


  72. AMARAPURKAR D, Somani V, Shah A
    Do we need to correct coagulation abnormalities prophylactically in cirrhotics undergoing invasive procedures? - A Dilemma.
    Hepatology. 2016 Sep 17. doi: 10.1002/hep.28830.
    PubMed     Text format    


  73. ABRALDES JG, Bureau C, Stefanescu H, Augustin S, et al
    Non-invasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: The "Anticipate" study.
    Hepatology. 2016 Sep 17. doi: 10.1002/hep.28824.
    PubMed     Text format     Abstract available


  74. RENOU C, Lesgourgues B, Macaigne G, Pauwels A, et al
    Hepatitis E in decompensated alcoholic cirrhosis.
    Hepatology. 2016 Sep 12. doi: 10.1002/hep.28792.
    PubMed     Text format    


    August 2016
  75. LALEMAN W, Trebicka J, Verbeke L
    Evolving insights in the pathophysiology of complications of cirrhosis: The Farnesoid-X receptor (FXR) to the rescue?
    Hepatology. 2016 Aug 17. doi: 10.1002/hep.28771.
    PubMed     Text format    


  76. FARVARDIN S, Patel J, Khambaty M, Yerokun OA, et al
    Patient-Reported Barriers are Associated with Lower HCC Surveillance Rates in Patients with Cirrhosis.
    Hepatology. 2016 Aug 17. doi: 10.1002/hep.28770.
    PubMed     Text format     Abstract available


  77. GOLDBERG DS, Taddei TH, Serper M, Mehta R, et al
    Identifying barriers to hepatocellular carcinoma surveillance in a national sample of patients with cirrhosis.
    Hepatology. 2016 Aug 17. doi: 10.1002/hep.28765.
    PubMed     Text format     Abstract available


  78. SALLOUM S, Holmes JA, Jindal R, Bale SS, et al
    HIV/HCV in hepatic and stellate cell lines reveals cooperative profibrotic transcriptional activation between viruses and cell types.
    Hepatology. 2016 Aug 17. doi: 10.1002/hep.28766.
    PubMed     Text format     Abstract available


  79. BIHARI C, Anand L, Rooge S, Kumar D, et al
    Bone Marrow Stem Cells and its Niche Components are Adversely Affected in Advanced Cirrhosis of Liver.
    Hepatology. 2016 Aug 3. doi: 10.1002/hep.28754.
    PubMed     Text format     Abstract available


  80. CLARIA J, Stauber RE, Coenraad MJ, Moreau R, et al
    systemic inflammation in decompensated cirrhosis. Characterization and role in acute-on-chronic liver failure.
    Hepatology. 2016 Aug 2. doi: 10.1002/hep.28740.
    PubMed     Text format     Abstract available


  81. DROLZ A, Fuhrmann V
    Reply to "Anticoagulation with i.v. unfractionated heparin and major bleeding in cirrhosis".
    Hepatology. 2016 Aug 2. doi: 10.1002/hep.28757.
    PubMed     Text format    


    July 2016
  82. QI X, De Stefano V, Guo X
    Anticoagulation with i.v. unfractionated heparin and major bleeding in cirrhosis.
    Hepatology. 2016 Jul 30. doi: 10.1002/hep.28743.
    PubMed     Text format    


  83. DAM G, Vilstrup H, Watson H, Jepsen P, et al
    Proton Pump Inhibitors as a Risk Factor for Hepatic Encephalopathy and Spontaneous Bacterial Peritonitis in Cirrhosis Patients With Ascites.
    Hepatology. 2016 Jul 30. doi: 10.1002/hep.28737.
    PubMed     Text format     Abstract available


  84. MAROT A, Trepo E, Doerig C, Moreno C, et al
    SEMS should be considered in patients with cirrhosis and uncontrolled variceal bleeding.
    Hepatology. 2016 Jul 30. doi: 10.1002/hep.28738.
    PubMed     Text format    


  85. LANGBERG KM, Taddei TH
    Balancing quality with quantity: The role of palliative care in managing decompensated cirrhosis.
    Hepatology. 2016 Jul 7. doi: 10.1002/hep.28717.
    PubMed     Text format    


    June 2016
  86. KALAMBOKIS GN, Oikonomou A, Christou L, Baltayiannis G, et al
    High von Willebrand factor antigen levels and procoagulant imbalance may be involved in both increasing severity of cirrhosis and portal vein thrombosis.
    Hepatology. 2016 Jun 27. doi: 10.1002/hep.28703.
    PubMed     Text format    


  87. GANNE-CARRIE N, Layese R, Bourcier V, Cagnot C, et al
    Nomogram for individualized prediction of hepatocellular carcinoma occurrence in HCV-cirrhosis (ANRS CO12 CirVir).
    Hepatology. 2016 Jun 27. doi: 10.1002/hep.28702.
    PubMed     Text format     Abstract available


  88. KANG DJ, Betrapally NS, Ghosh SA, Sartor RB, et al
    Gut microbiota drive the development of neuro-inflammatory response in cirrhosis.
    Hepatology. 2016 Jun 23. doi: 10.1002/hep.28696.
    PubMed     Text format     Abstract available


  89. SUK KT, Yoon JH, Kim MY, Kim CW, et al
    Transplantation with Autologous Bone Marrow-Derived Mesenchymal Stem Cells for Alcoholic Cirrhosis: Phase 2 Trial.
    Hepatology. 2016 Jun 23. doi: 10.1002/hep.28693.
    PubMed     Text format     Abstract available


  90. ULVELING D, Le Clerc S, Cobat A, Labib T, et al
    A new 3p25 locus is associated with liver fibrosis progression in HIV/HCV co-infected patients.
    Hepatology. 2016 Jun 23. doi: 10.1002/hep.28695.
    PubMed     Text format     Abstract available


  91. CUI J, Chen CH, Lo MT, Schork N, et al
    Shared genetic effects between hepatic steatosis and fibrosis: A prospective twin study.
    Hepatology. 2016 Jun 17. doi: 10.1002/hep.28674.
    PubMed     Text format     Abstract available


  92. DI PASCOLI M, Zampieri F, Verardo A, Pesce P, et al
    Inhibition of EETs production in cirrhotic rats has beneficial effects on portal hypertension by reducing splanchnic vasodilation.
    Hepatology. 2016 Jun 16. doi: 10.1002/hep.28686.
    PubMed     Text format     Abstract available


  93. SETIAWAN VW, Stram DO, Porcel J, Lu SC, et al
    Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: The Multiethnic Cohort.
    Hepatology. 2016 Jun 15. doi: 10.1002/hep.28677.
    PubMed     Text format     Abstract available


    May 2016
  94. MATSUURA K, De Giorgi V, Schechterly C, Wang RY, et al
    Circulating let-7 levels in plasma and extracellular vesicles correlate with hepatic fibrosis progression in chronic hepatitis C.
    Hepatology. 2016 May 26. doi: 10.1002/hep.28660.
    PubMed     Text format     Abstract available


  95. PAPATHEODORIDIS G, Vlachogiannakos I, Cholongitas E, Wursthorn K, et al
    Discontinuation of oral antivirals in chronic hepatitis B: A systematic review.
    Hepatology. 2016;63:1481-1492.
    PubMed     Text format     Abstract available


  96. LIASKOU E, Klemsdal Henriksen EK, Holm K, Kaveh F, et al
    High-throughput T-cell receptor sequencing across chronic liver diseases reveals distinct disease-associated repertoires.
    Hepatology. 2016;63:1608-19.
    PubMed     Text format     Abstract available


    April 2016
  97. DROLZ A, Horvatits T, Roedl K, Rutter K, et al
    Coagulation parameters and major bleeding in critically ill patients with cirrhosis.
    Hepatology. 2016 Apr 28. doi: 10.1002/hep.28628.
    PubMed     Text format     Abstract available


  98. TANG H, Bai HX, Su C, Lee AM, et al
    The effect of cirrhosis on radiogenomic biomarker's ability to predict microvascular invasion and outcome in hepatocellular carcinoma.
    Hepatology. 2016 Apr 26. doi: 10.1002/hep.28620.
    PubMed     Text format    


  99. MALIZIA G, Cervello OV, D'Amico G
    Statins in cirrhosis: The magic pill?
    Hepatology. 2016 Apr 26. doi: 10.1002/hep.28616.
    PubMed     Text format    


  100. WU N, Meng F, Invernizzi P, Bernuzzi F, et al
    The secretin/secretin receptor axis modulates liver fibrosis through changes in TGF-beta1 biliary secretion.
    Hepatology. 2016 Apr 26. doi: 10.1002/hep.28622.
    PubMed     Text format     Abstract available


  101. LIU J, Yang HI, Lee MH, Jen CL, et al
    Serum Levels of Hepatitis B Surface Antigen and DNA Can Predict Inactive Carriers With Low Risk of Disease Progression.
    Hepatology. 2016 Apr 15. doi: 10.1002/hep.28552.
    PubMed     Text format     Abstract available


  102. LI KK, Trivedi PJ, Von Heimendahl S, Bruns T, et al
    Hepatocellular carcinoma surveillance in hepatitis B virus-infected individuals: Who and how?
    Hepatology. 2016;63:1394-5.
    PubMed     Text format    


  103. BARTNECK M, Fech V, Ehling J, Govaere O, et al
    Histidine-rich glycoprotein promotes macrophage activation and inflammation in chronic liver disease.
    Hepatology. 2016;63:1310-24.
    PubMed     Text format     Abstract available


  104. PIANO S, Fasolato S, Salinas F, Romano A, et al
    The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: Results of a randomized, controlled clinical trial.
    Hepatology. 2016;63:1299-309.
    PubMed     Text format     Abstract available


    March 2016
  105. KALAMBOKIS GN, Christodoulou D, Baltayiannis G, Christou L, et al
    Propranolol use beyond 6 months increases mortality in patients with Child-Pugh C cirrhosis and ascites.
    Hepatology. 2016 Mar 26. doi: 10.1002/hep.28575.
    PubMed     Text format    


  106. KANWAL F, Asch SM, Kramer JR, Cao Y, et al
    Early Outpatient Follow-up and 30-day Outcomes in Patients Hospitalized with Cirrhosis.
    Hepatology. 2016 Mar 17. doi: 10.1002/hep.28558.
    PubMed     Text format     Abstract available


  107. MCPHAIL MJ, Auzinger G, Bernal W, Wendon JA, et al
    Decisions on futility in patients with cirrhosis and organ failure.
    Hepatology. 2016 Mar 7. doi: 10.1002/hep.28539.
    PubMed     Text format    


  108. GUSTOT T, Fernandez J, Pavesi M, Arroyo V, et al
    Reply to "Decisions on futility in patients with cirrhosis and organ failure".
    Hepatology. 2016 Mar 7. doi: 10.1002/hep.28538.
    PubMed     Text format    


    February 2016
  109. SIMON TG, Bonilla H, Yan P, Chung RT, et al
    Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and HCC, among patients with HCV Results from ERCHIVES.
    Hepatology. 2016 Feb 18. doi: 10.1002/hep.28506.
    PubMed     Text format     Abstract available


  110. VILARINHO S, Sari S, Yilmaz G, Stiegler AL, et al
    Recurrent Recessive Mutation in DGUOK Causes Idiopathic Non-Cirrhotic Portal Hypertension.
    Hepatology. 2016 Feb 13. doi: 10.1002/hep.28499.
    PubMed     Text format     Abstract available


  111. CUI J, Heba E, Hernandez C, Haufe W, et al
    Magnetic resonance elastography is superior to acoustic radiation force impulse for the Diagnosis of fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease: A prospective study.
    Hepatology. 2016;63:453-61.
    PubMed     Text format     Abstract available


    January 2016
  112. LEROY V, Angus P, Bronowicki JP, Dore GJ, et al
    Daclatasvir, Sofosbuvir, and Ribavirin for Hepatitis C Virus Genotype 3 and Advanced Liver Disease: A Randomized Phase III Study (ALLY-3+).
    Hepatology. 2016 Jan 28. doi: 10.1002/hep.28473.
    PubMed     Text format     Abstract available


  113. TAPPER EB
    Challenge accepted: Confronting readmissions for our patients with cirrhosis.
    Hepatology. 2016 Jan 25. doi: 10.1002/hep.28471.
    PubMed     Text format    


  114. SACK J, Garcia-Tsao G
    Variceal hemorrhage in a patient with HCV cirrhosis in whom liver synthetic function had normalized after viral elimination.
    Hepatology. 2016 Jan 25. doi: 10.1002/hep.28470.
    PubMed     Text format    


  115. KWO P, Gitlin N, Nahass R, Bernstein D, et al
    Simeprevir Plus Sofosbuvir (12 and 8 Weeks) in HCV Genotype 1-Infected Patients Without Cirrhosis: OPTIMIST-1, a Phase 3, Randomized Study.
    Hepatology. 2016 Jan 22. doi: 10.1002/hep.28467.
    PubMed     Text format     Abstract available


  116. NORONHA FERREIRA C, Seijo S, Plessier A, Silva-Junior G, et al
    Natural history and management of esophagogastric varices in chronic non-cirrhotic non-tumoral portal vein thrombosis.
    Hepatology. 2016 Jan 22. doi: 10.1002/hep.28466.
    PubMed     Text format     Abstract available


  117. POORDAD F, Schiff ER, Vierling JM, Landis C, et al
    Daclatasvir With Sofosbuvir and Ribavirin for HCV Infection With Advanced Cirrhosis or Post-Liver Transplant Recurrence.
    Hepatology. 2016 Jan 11. doi: 10.1002/hep.28446.
    PubMed     Text format     Abstract available


  118. DESAI SS, Tung JC, Zhou VX, Grenert JP, et al
    Physiological Ranges of Matrix Rigidity Modulate Primary Mouse Hepatocyte Function In Part Through Hepatocyte Nuclear Factor 4 Alpha.
    Hepatology. 2016 Jan 11. doi: 10.1002/hep.28450.
    PubMed     Text format     Abstract available



  119. Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: A systematic review and meta-analysis.
    Hepatology. 2016;63:349.
    PubMed     Text format    


  120. GIANNINI EG, Stravitz RT, Caldwell SH
    Portal vein thrombosis and chronic liver disease progression: The closer you look the more you see.
    Hepatology. 2016;63:342-3.
    PubMed     Text format    


  121. KOEHLER EM, Plompen EP, Schouten JN, Hansen BE, et al
    Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study.
    Hepatology. 2016;63:138-47.
    PubMed     Text format     Abstract available


    December 2015
  122. OH Y, Park O, Swierczewska M, Hamilton JP, et al
    Systemic PEGylated TRAIL treatment ameliorates liver cirrhosis in rats by eliminating activated hepatic stellate cells.
    Hepatology. 2015 Dec 28. doi: 10.1002/hep.28432.
    PubMed     Text format     Abstract available


  123. REIN DB, Borton J, Liffmann DK, Wittenborn JS, et al
    The burden of hepatitis C to the United States medicare system in 2009: Descriptive and economic characteristics.
    Hepatology. 2015 Dec 28. doi: 10.1002/hep.28430.
    PubMed     Text format     Abstract available


  124. INTAGLIATA NM, Caldwell SH, Porte RJ, Lisman T, et al
    Prediction of bleeding in cirrhosis patients: Is the forecast any clearer?
    Hepatology. 2015 Dec 24. doi: 10.1002/hep.28426.
    PubMed     Text format    


  125. LAWITZ E, Matusow G, DeJesus E, Yoshida EM, et al
    Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A Phase 3 study (OPTIMIST-2).
    Hepatology. 2015 Dec 24. doi: 10.1002/hep.28422.
    PubMed     Text format     Abstract available


  126. TANOUE S, Kaplan DE
    CD14 regulatory Dendritic Cells in Hepatocellular Carcinoma and Cirrhotic patients.
    Hepatology. 2015 Dec 24. doi: 10.1002/hep.28419.
    PubMed     Text format    


  127. SAAB S, Park SH, Mizokami M, Omata M, et al
    Safety and Efficacy of Ledipasvir/Sofosbuvir for the Treatment of Genotype 1 Hepatitis C in Subjects Aged 65 Years or Older.
    Hepatology. 2015 Dec 24. doi: 10.1002/hep.28425.
    PubMed     Text format     Abstract available


  128. BAJAJ JS, Reddy KR, Tandon P, Wong F, et al
    The Three-Month Readmission Rate Remains Unacceptably High in a Large North American Cohort of Cirrhotic Patients.
    Hepatology. 2015 Dec 21. doi: 10.1002/hep.28414.
    PubMed     Text format     Abstract available


  129. LOCATELLI L, Cadamuro M, Spirli C, Fiorotto R, et al
    Macrophage recruitment by fibrocystin-defective biliary epithelial cells promotes portal fibrosis in congenital hepatic fibrosis.
    Hepatology. 2015 Dec 8. doi: 10.1002/hep.28382.
    PubMed     Text format     Abstract available


    November 2015
  130. BLASI A, Hernandez-Gea V, Reverter JC, Garcia-Pagan JC, et al
    Quality of anticoagulation and outcome of bleeding in cirrhosis.
    Hepatology. 2015 Nov 25. doi: 10.1002/hep.28371.
    PubMed     Text format    


  131. QI X, De Stefano V, Guo X
    Quality of anticoagulation and outcome of bleeding in cirrhosis.
    Hepatology. 2015 Nov 25. doi: 10.1002/hep.28369.
    PubMed     Text format    


  132. BOSSEN L, Krag A, Vilstrup H, Watson H, et al
    Non-selective beta-blockers do not affect mortality in cirrhosis patients with ascites: Post hoc analysis of three RCTs with 1198 patients.
    Hepatology. 2015 Nov 24. doi: 10.1002/hep.28352.
    PubMed     Text format     Abstract available


  133. LOK AS, McMahon BJ, Brown RS Jr, Wong JB, et al
    Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis.
    Hepatology. 2015 Nov 13. doi: 10.1002/hep.28280.
    PubMed     Text format     Abstract available


  134. DESBOROUGH MJ, Jairath V
    Thrombelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy.
    Hepatology. 2015 Nov 6. doi: 10.1002/hep.28336.
    PubMed     Text format    


  135. MERLI M, Lucidi C, Di Gregorio V, Lattanzi B, et al
    An empirical broad spectrum antibiotic therapy in Healthcare-Associated infections improves survival in cirrhotics: A randomized trial.
    Hepatology. 2015 Nov 3. doi: 10.1002/hep.28332.
    PubMed     Text format     Abstract available


  136. FERNANDEZ J, Tandon P, Mensa J, Garcia-Tsao G, et al
    Antibiotic prophylaxis in cirrhosis: Good and bad.
    Hepatology. 2015 Nov 3. doi: 10.1002/hep.28330.
    PubMed     Text format     Abstract available


  137. LEUNG DH, Khan M, Minard CG, Guffey D, et al
    Aspartate aminotransferase to platelet ratio and fibrosis-4 as biomarkers in biopsy-validated pediatric cystic fibrosis liver disease.
    Hepatology. 2015;62:1576-83.
    PubMed     Text format     Abstract available


    October 2015
  138. LEE MS
    Clinical characteristics and outcomes of pyogenic vertebral osteomyelitis in patients with cirrhosis.
    Hepatology. 2015 Oct 30. doi: 10.1002/hep.28319.
    PubMed     Text format    


  139. LAI JC, Dodge JL, Sen S, Covinsky K, et al
    Functional Decline in Patients with Cirrhosis Awaiting Liver Transplantation: Results from the Functional Assessment in Liver Transplantation (FrAILT) Study.
    Hepatology. 2015 Oct 30. doi: 10.1002/hep.28316.
    PubMed     Text format     Abstract available


  140. BURZA MA, Motta BM, Mancina RM, Pingitore P, et al
    DEPDC5 variants increase fibrosis progression in Europeans with chronic HCV infection.
    Hepatology. 2015 Oct 30. doi: 10.1002/hep.28322.
    PubMed     Text format     Abstract available


  141. ALBILLOS A, Martinez J, Tellez L
    Continued controversy over the safety of beta-blockers in decompensated cirrhosis.
    Hepatology. 2015 Oct 16. doi: 10.1002/hep.28293.
    PubMed     Text format    


  142. RAHIMI RS, O'Leary JG
    Transfusing Common Sense Instead of Blood Products into Coagulation Testing in Patients with Cirrhosis: Overtreatment not equal Safety.
    Hepatology. 2015 Oct 16. doi: 10.1002/hep.28291.
    PubMed     Text format    


  143. AHMED A, Perumpail RB, Harrison SA
    High Prevalence of Hepatic Fibrosis in the Setting of Coexisting Diabetes and Hepatic Steatosis: A Case for Selective Screening in General Population?
    Hepatology. 2015 Oct 9. doi: 10.1002/hep.28277.
    PubMed     Text format    


  144. RIPOLL C
    Non-invasive predictors of fibrosis in NASH with and without cirrhosis, just as good as histology (and HVPG?).
    Hepatology. 2015 Oct 8. doi: 10.1002/hep.28273.
    PubMed     Text format    


  145. PENG ZW, Ikenaga N, Liu SB, Sverdlov DY, et al
    Integrin alphavbeta6 critically regulates hepatic progenitor cell function and promotes ductular reaction, fibrosis and tumorigenesis.
    Hepatology. 2015 Oct 8. doi: 10.1002/hep.28274.
    PubMed     Text format     Abstract available


  146. PETTA S, Maida M, Macaluso FS, Di Marco V, et al
    The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease.
    Hepatology. 2015;62:1101-10.
    PubMed     Text format     Abstract available


    September 2015
  147. VILLANUEVA C, Albillos A, Genesca J, Abraldes JG, et al
    Development of hyperdynamic circulation and response to beta-blockers in compensated cirrhosis with portal hypertension.
    Hepatology. 2015 Sep 30. doi: 10.1002/hep.28264.
    PubMed     Text format     Abstract available


  148. FERNANDEZ-VARO G, Oro D, Cable EE, Reichenbach V, et al
    Vasopressin 1a receptor partial agonism increases sodium excretion and reduces portal hypertension and ascites in cirrhotic rats.
    Hepatology. 2015 Sep 24. doi: 10.1002/hep.28250.
    PubMed     Text format     Abstract available


  149. YOSHIMURA K, Okanoue T, Ebise H, Iwasaki T, et al
    Identification of novel noninvasive markers for diagnosing nonalcoholic steatohepatitis and related fibrosis by data mining.
    Hepatology. 2015 Sep 21. doi: 10.1002/hep.28226.
    PubMed     Text format     Abstract available


  150. COUSIEN A, Tran VC, Deuffic-Burban S, Jauffret-Roustide M, et al
    Hepatitis c treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs.
    Hepatology. 2015 Sep 21. doi: 10.1002/hep.28227.
    PubMed     Text format     Abstract available


  151. BEUERS U, Gershwin ME, Gish RG, Invernizzi P, et al
    Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'.
    Hepatology. 2015 Sep 15. doi: 10.1002/hep.28140.
    PubMed     Text format    


  152. DE PIETRI L, Bianchini M, Montalti R, De Maria N, et al
    Thrombelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy. A randomized controlled trial.
    Hepatology. 2015 Sep 4. doi: 10.1002/hep.28148.
    PubMed     Text format     Abstract available


  153. BUTLER NS, Schmidt NW
    Erythropoietin-producing hepatocellular receptor B2 receptor tyrosine kinase: A novel regulator of infection- and inflammation-induced liver fibrosis.
    Hepatology. 2015;62:680-3.
    PubMed     Text format    


    August 2015
  154. GORHAM JD, Gleeson MW
    Cirrhosis and dysbiosis: New insights from next generation sequencing.
    Hepatology. 2015 Aug 27. doi: 10.1002/hep.28133.
    PubMed     Text format    


  155. TRIVEDI PJ, Corpechot C, Pares A, Hirschfield GM, et al
    Risk Stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists.
    Hepatology. 2015 Aug 20. doi: 10.1002/hep.28128.
    PubMed     Text format     Abstract available


  156. SHIMODA S, Hisamoto S, Harada K, Iwasaka S, et al
    Natural killer cells regulate T cell immune responses in primary biliary cirrhosis.
    Hepatology. 2015 Aug 11. doi: 10.1002/hep.28122.
    PubMed     Text format     Abstract available


  157. SILVA-JUNIOR G, Baiges A, Turon F, Torres F, et al
    The prognostic value of HVPG in patients with cirrhosis is highly dependent on the accuracy of the technique.
    Hepatology. 2015 Aug 3. doi: 10.1002/hep.28031.
    PubMed     Text format     Abstract available


  158. TOROK NJ, Dranoff JA, Schuppan D, Friedman SL, et al
    Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014.
    Hepatology. 2015;62:627-34.
    PubMed     Text format     Abstract available


  159. MCLAREN CE, Emond MJ, Subramaniam VN, Phatak PD, et al
    Exome sequencing in HFE C282Y homozygous men with extreme phenotypes identifies a GNPAT variant associated with severe iron overload.
    Hepatology. 2015;62:429-39.
    PubMed     Text format     Abstract available


    July 2015
  160. CARBONE M, Sharp SJ, Flack S, Paximadas D, et al
    The UK-PBC Risk Scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cirrhosis.
    Hepatology. 2015 Jul 29. doi: 10.1002/hep.28017.
    PubMed     Text format     Abstract available


  161. HENRY ZH, Northup PG
    Baclofen for the treatment of muscle cramps in patients with cirrhosis: A new alternative.
    Hepatology. 2015 Jul 14. doi: 10.1002/hep.27988.
    PubMed     Text format     Abstract available


  162. BAJAJ JS
    Liver Capsule: Hepatic Encephalopathy.
    Hepatology. 2015 Jul 14. doi: 10.1002/hep.27984.
    PubMed     Text format    


  163. KUMADA H, Chayama K, Rodrigues-Jr L, Suzuki F, et al
    Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir for HCV Genotype 1b-infected Japanese Patients With or Without Cirrhosis.
    Hepatology. 2015 Jul 3. doi: 10.1002/hep.27972.
    PubMed     Text format     Abstract available


  164. KAYADIBI H, Sertoglu E, Uyanik M
    Biochemical markers, liver biopsy, or magnetic resonance elastography to detect or exclude advanced fibrosis in patients with nonalcoholic fatty liver disease.
    Hepatology. 2015;62:324-5.
    PubMed     Text format    


    June 2015
  165. MANENTI A, Pavesi E, Farinetti A, Colasanto D, et al
    A morpho-dynamic evaluation of the portal and hepatic venous system in cirrhosis can predict a progression of portal hypertension.
    Hepatology. 2015 Jun 30. doi: 10.1002/hep.27967.
    PubMed     Text format    


  166. AQEL B, Pungpapong S, Leise M, Werner KT, et al
    Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis.
    Hepatology. 2015 Jun 11. doi: 10.1002/hep.27937.
    PubMed     Text format     Abstract available


  167. JIMENEZ CALVENTE C, Sehgal A, Popov Y, Kim YO, et al
    Specific hepatic delivery of procollagen alpha1(I) siRNA in lipid-like nanoparticles resolves liver fibrosis.
    Hepatology. 2015 Jun 10. doi: 10.1002/hep.27936.
    PubMed     Text format     Abstract available


  168. SAXENA V, Nyberg L, Pauly M, Dasgupta A, et al
    Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C Infected Patients with Compensated and Decompensated Cirrhosis.
    Hepatology. 2015 Jun 1. doi: 10.1002/hep.27922.
    PubMed     Text format     Abstract available


  169. PIND ML, Moller S, Faqir N, Bendtsen F, et al
    Predictive value of indocyanine green retention test and indocyanine green clearance in Child-Pugh class A patients.
    Hepatology. 2015;61:2112-3.
    PubMed     Text format    


  170. LISOTTI A, Azzaroli F, Mazzella G
    Reply: To PMID 24038116.
    Hepatology. 2015;61:2113-4.
    PubMed     Text format    


  171. THAPA M, Chinnadurai R, Velazquez VM, Tedesco D, et al
    Liver fibrosis occurs through dysregulation of MyD88-dependent innate B-cell activity.
    Hepatology. 2015;61:2067-79.
    PubMed     Text format     Abstract available


  172. KANTARI-MIMOUN C, Castells M, Klose R, Meinecke AK, et al
    Resolution of liver fibrosis requires myeloid cell-driven sinusoidal angiogenesis.
    Hepatology. 2015;61:2042-55.
    PubMed     Text format     Abstract available


    May 2015
  173. SULTANIK P, Sogni P, Meritet J, Pol S, et al
    Patients with Chronic Hepatitis B should be screened for Hepatocellular Carcinoma Regardless of Liver Stiffness Measurement.
    Hepatology. 2015 May 23. doi: 10.1002/hep.27904.
    PubMed     Text format    


  174. PATEL VC, Shawcross DL
    Salivary microbiota-immune profiling in cirrhosis: could this be the non-invasive strategy that will revolutionise prognostication in hepatology?
    Hepatology. 2015 May 22. doi: 10.1002/hep.27870.
    PubMed     Text format    


  175. KIM MN, Han KH, Kim SU
    Reply to "Patients with chronic hepatitis b should be screened for hepatocellular carcinoma regardless of liver stiffness measurement."
    Hepatology. 2015 May 20. doi: 10.1002/hep.27903.
    PubMed     Text format    


  176. SINN DH, Lee J, Goo J, Kim K, et al
    Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load.
    Hepatology. 2015 May 11. doi: 10.1002/hep.27889.
    PubMed     Text format     Abstract available


  177. ALQAHTANI SA, Afdhal N, Zeuzem S, Gordon S, et al
    Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hcv genotype 1 infection: Analysis of phase 3 ION trials.
    Hepatology. 2015 May 11. doi: 10.1002/hep.27890.
    PubMed     Text format     Abstract available


  178. EKSTEDT M, Hagstrom H, Nasr P, Fredrikson M, et al
    Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.
    Hepatology. 2015;61:1547-54.
    PubMed     Text format     Abstract available


  179. TORRES DM, Harrison SA
    Nonalcoholic fatty liver disease: Fibrosis portends a worse prognosis.
    Hepatology. 2015;61:1462-4.
    PubMed     Text format    


    April 2015
  180. LIN CL, Kao JH
    Can noninvasive biomarkers replace liver biopsy for chronic hepatitis B?
    Hepatology. 2015 Apr 24. doi: 10.1002/hep.27865.
    PubMed     Text format    


  181. XIAO G, Shen J, Yan L
    Reply: HEP-14-0182 Can noninvasive biomarkers replace liver biopsy for chronic hepatitis B?
    Hepatology. 2015 Apr 24. doi: 10.1002/hep.27861.
    PubMed     Text format    


  182. VAN DER MEER AJ
    Value anti-HCV therapy by its clinical efficacy.
    Hepatology. 2015 Apr 18. doi: 10.1002/hep.27850.
    PubMed     Text format    


  183. WU L, Zhao J
    Does IL-22 protect against liver fibrosis in hepatitis C virus infection?
    Hepatology. 2015 Apr 18. doi: 10.1002/hep.27856.
    PubMed     Text format    


  184. BUTT AA, Yan P, Bonilla H, Abou-Samra AB, et al
    Effect of addition of statins to antiviral therapy in HCV infected persons: Results from ERCHIVES.
    Hepatology. 2015 Apr 6. doi: 10.1002/hep.27835.
    PubMed     Text format     Abstract available


  185. KO E, Jung ES, Jung G
    Telomerase reverse transcriptase promoter methylation is related to a risk of recurrence in hepatocellular carcinoma.
    Hepatology. 2015 Apr 4. doi: 10.1002/hep.27833.
    PubMed     Text format    


  186. NAULT JC, Calderaro J, Zucman-Rossi J
    Response to "telomerase reverse transcriptase promoter methylation is related to a risk of recurrence in hepatocellular carcinoma" by Ko E and colleagues.
    Hepatology. 2015 Apr 4. doi: 10.1002/hep.27827.
    PubMed     Text format    


  187. SCHRAMM C, Wahl I, Lohse AW
    Reply.
    Hepatology. 2015;61:1435.
    PubMed     Text format    


    March 2015
  188. MILANO M, Aghemo A, Mancina RM, Fischer J, et al
    TM6SF2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients.
    Hepatology. 2015 Mar 29. doi: 10.1002/hep.27811.
    PubMed     Text format     Abstract available


  189. KITSON MT, Sarrazin C, Toniutto P, Roberts SK, et al
    Relationship between vitamin D status and response to HCV therapy.
    Hepatology. 2015 Mar 21. doi: 10.1002/hep.27797.
    PubMed     Text format    


  190. PINEDA-TENOR D, Garcia-Alvarez M, Jimenez-Sousa MA, Fernandez-Rodriguez A, et al
    Reply to Kitson et al.: "Relationship between vitamin D status and response to HCV therapy".
    Hepatology. 2015 Mar 21. doi: 10.1002/hep.27796.
    PubMed     Text format    


  191. MIMCHE PN, Brady LM, Bray CF, Mimche SM, et al
    The receptor tyrosine kinase EphB2 promotes hepatic fibrosis in mice.
    Hepatology. 2015 Mar 17. doi: 10.1002/hep.27792.
    PubMed     Text format     Abstract available


    February 2015
  192. INNES HA, McDonald SA, Dillon JF, Allen S, et al
    Towards a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes.
    Hepatology. 2015 Feb 26. doi: 10.1002/hep.27766.
    PubMed     Text format     Abstract available


  193. GHONEM NS, Assis DN, Boyer JL
    On fibrates and cholestasis: A review.
    Hepatology. 2015 Feb 11. doi: 10.1002/hep.27744.
    PubMed     Text format     Abstract available


  194. PANG Q, Sen Xu X, Zhang JY, Qu K, et al
    FIB-4 as a prognostic model for patients with hepatitis B-associated hepatocellular carcinoma.
    Hepatology. 2015 Feb 2. doi: 10.1002/hep.27727.
    PubMed     Text format    


    January 2015
  195. POUPON R
    Liver alkaline phosphatase: A missing link between choleresis and biliary inflammation.
    Hepatology. 2015 Jan 20. doi: 10.1002/hep.27715.
    PubMed     Text format     Abstract available


  196. CHAYAMA K, Notsumata K, Kurosaki M, Sato K, et al
    Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hcv-infected patients.
    Hepatology. 2015 Jan 16. doi: 10.1002/hep.27705.
    PubMed     Text format     Abstract available


  197. FALLOWFIELD DJ
    Macrophage-derived VEGF and angiogenesis within the hepatic scar - new pathways unmasked in the resolution of fibrosis.
    Hepatology. 2015 Jan 10. doi: 10.1002/hep.27696.
    PubMed     Text format    


  198. OBACH D, Yazdanpanah Y, Esmat G, Avihingsanon A, et al
    How to optimize HCV treatment impact on life years saved in resource-constrained countries.
    Hepatology. 2015 Jan 10. doi: 10.1002/hep.27691.
    PubMed     Text format     Abstract available


    December 2014
  199. MACIAS J, Mancebo M, Marquez M, Merino D, et al
    Low risk of liver decompensation among human immunodeficiency virus/hepatitis c virus-coinfected patients with mild fibrosis in the short-term.
    Hepatology. 2014 Dec 24. doi: 10.1002/hep.27674.
    PubMed     Text format     Abstract available


  200. SUH B, Park S, Shin DW, Yun JM, et al
    High liver fibrosis index FIB-4 highly predictive of hepatocellular carcinoma in chronic hepatitis B carriers.
    Hepatology. 2014 Dec 12. doi: 10.1002/hep.27654.
    PubMed     Text format     Abstract available


  201. PAN RL, Xiang LX, Wang P, Liu XY, et al
    FGF2 attenuates hepatic fibrosis via epigenetic downregulation of Delta-like1.
    Hepatology. 2014 Dec 11. doi: 10.1002/hep.27649.
    PubMed     Text format     Abstract available


  202. O'MAHONY F, Wroblewski K, O'Byrne SM, Jiang H, et al
    Liver X receptors balance lipid stores in hepatic stellate cells via Rab18, a retinoid responsive lipid droplet protein.
    Hepatology. 2014 Dec 6. doi: 10.1002/hep.27645.
    PubMed     Text format     Abstract available


  203. CHIANG CJ, Yang YW, Chen JD, You SL, et al
    Significant reduction in end-stage liver diseases burden through national viral hepatitis therapy program in Taiwan.
    Hepatology. 2014 Dec 5. doi: 10.1002/hep.27630.
    PubMed     Text format     Abstract available


    October 2014
  204. SCORLETTI E, Bhatia L, McCormick KG, Clough GF, et al
    Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* study.
    Hepatology. 2014;60:1211-21.
    PubMed     Text format     Abstract available


  205. CHEN RP, Chen C, Yu JY, Huang XL, et al
    Trial sequence meta-analysis can reject false-positive result calculated from conventional meta-analysis.
    Hepatology. 2014;60:1442-3.
    PubMed     Text format    


  206. BERNARDI M, Caraceni P, Navickis RJ, Wilkes MM, et al
    Reply: To PMID 22095893.
    Hepatology. 2014;60:1443-5.
    PubMed     Text format    


    August 2014
  207. DELEVE LD
    Liver sinusoidal endothelial cells in hepatic fibrosis.
    Hepatology. 2014 Aug 18. doi: 10.1002/hep.27376.
    PubMed     Text format     Abstract available


    May 2014
  208. LLEO A, Zhang W, McDonald WH, Seeley EH, et al
    Shotgun Proteomics: Identification of Unique Protein Profiles of Apoptotic Bodies from Biliary Epithelial Cells.
    Hepatology. 2014 May 20. doi: 10.1002/hep.27230.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Cirrhosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: